Akynzeo
netupitant / palonosetron
Table of contents
Overview
Akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adults with cancer who are receiving chemotherapy (medicines to treat cancer).
Some chemotherapy is known to induce severe nausea and vomiting, and Akynzeo is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy containing the cancer medicine cisplatin, or other chemotherapies that are moderately emetogenic.
Akynzeo is available as capsules and as a powder to be made up into a solution for injection. It contains the active substances netupitant and palonosetron (capsules) or fosnetupitant and palonosetron (powder).
-
List item
Akynzeo : EPAR - Medicine overview (PDF/110.16 KB)
First published: 23/06/2015
Last updated: 19/03/2020
EMA/16010/2020 -
-
List item
Akynzeo : EPAR - Risk-management-plan summary (PDF/163.51 KB)
First published: 23/06/2015
Last updated: 17/11/2021
Authorisation details
Product details | |
---|---|
Name |
Akynzeo
|
Agency product number |
EMEA/H/C/003728
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
A04AA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Helsinn Birex Pharmaceuticals Ltd
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
27/05/2015
|
Contact address |
Damastown |
Product information
05/09/2023 Akynzeo - EMEA/H/C/003728 - N/0050
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiemetics and antinauseants
Therapeutic indication
Akynzeo is indicated in adults for the:
- Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.
- Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.